Social Media Ideas for Bntx

Is BioNTech Stock a No-Brainer Buy on the Dip?

The company is coming back into the spotlight thanks to recent developments.

ImmunityBio: ANKTIVA's Commercial Momentum Supports A Buy

BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?

Both have attracted considerable attention from Wall Street recently.

BioNTech Just Named a New CEO. Here's What Guido Oelkers' Appointment Means for the Stock.

BioNTech is preparing for its next phase.

TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors

BioXcel files for Chapter 11, will sell assets to Teva

Cathie Wood Just Bet Big on This Biotech Stock

MRNA Stock Gets a Shot in the Arm as FDA Approves Moderna Flu Vaccine

<![CDATA[BioNTech Terminates Phase II Clinical Trial for Cevumeran ]]>

Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?

BioNTech deep in the red as demand for vaccines falls

Lower global demand for the Covid-19 vaccine has cost BioNTech a loss running into the billions in the first half of 2026, reported dpa. The German company made a net loss of €1...

Moderna (MRNA) Soars 179% as Melanoma Therapy Candidate Rewrites Growth Story

<![CDATA[Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia]]>

New drug data could lift shares of this biotechnology stock, Truist says

Biogen could see more upside if it publishes positive results from recent trials linked to kidney and Alzheimer's treatments, Truist Securities says. 

BioXcel

BioXcel Anonymous (not verified) Sun, 08/30/2026 - 09:43 field_thread_url https://cafepharma.com/boards/threads/bioxcel.674502/ board na...

This GLP-1 Stock Could Double by 2030. Here's Why

Investors need to ask tough questions before initiating a position in this biotech company.

XBI: Big Pharma Can Keep The 76% Rally Going

BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play

AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice

AbCellera has reported phase 2 results “beyond even the most aggressive upside scenario” that its CEO dared to consider, boosting the biotech’s chances of challenging Astellas and...

Bavarian Nordic A/S 2026 Q2 - Results - Earnings Call Presentation

Baxfendy Approval

Baxfendy Approval Anonymous (not verified) Sat, 08/22/2026 - 06:38 field_thread_url https://cafepharma.com/boards/threads/baxfendy-approval.716800/...

Forte Biosciences shares jump after $2.2 billion takeover agreement with argenx

Market Update: BTI, MCHP, APTV, TWLO, CAVA

What This Immunome Sale Means a Day Before a Big FDA Milestone

Barchas maintains 211,763 residual shares through direct and indirect holdings following execution under a Rule 10b5-1 trading plan adopted in March 2026.